13F filer · CIK 1667082
Biomark Capital Management Co. LLC
GREENWICH, CT · filing since Q4 2015 · last filing Oct 24, 2018
Reported value
$77.9M
+$5.2M vs prior
Positions
3
New / sold out
0 / 0
Added / reduced
1 / 0
Turnover
0.0%
buys $18.7M · sells $0
Top-10 weight
100.0%
Biggest buys vs Q1 2016
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Added | JUNO THERAPEUTICS, INC. | +603,364 | +37.6% | +$18.7M |
Biggest sells vs Q1 2016
No reduced or sold positions this quarter.
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q2 2016
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | JUNO THERAPEUTICS, INC.COMMON STOCK | 2,205,926 | $68.5M | 87.91% |
| 2 | ADMA BIOLOGICS, INC.COMMON STOCK | 1,433,304 | $9.3M | 11.94% |
| 3 | MABVAX THERAPEUTICS HOLDINGS, INC.COMMON STOCK | 197,641 | $119.0K | 0.15% |